Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
Abraham
J T
JT
Department of Child and Family Psychiatry, Brown University, Providence, Rhode Island, USA.
Brown
R
R
Meltzer
H Y
HY
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004409:Dyskinesia, Drug-Induced / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009460:Neurologic Examination / Q000187:drug effects; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects*
D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D017366:Serotonin Receptor Agonists; D017374:Paroxetine; D018170:Sumatriptan; D003024:Clozapine